Patnaik MM - Search Results

1

Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patients.

Patnaik MM, Hanson CA, Hodnefield JM, Lasho TL, Finke CM, Knudson RA, Ketterling RP, Pardanani A, Tefferi A. Patnaik MM, et al. Leukemia. 2012 Jan;26(1):101-5. doi: 10.1038/leu.2011.298. Epub 2011 Oct 28. Leukemia. 2012. PMID: 22033490

2

FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature.

Pardanani A, Ketterling RP, Li CY, Patnaik MM, Wolanskyj AP, Elliott MA, Camoriano JK, Butterfield JH, Dewald GW, Tefferi A. Pardanani A, et al. Among authors: patnaik mm. Leuk Res. 2006 Aug;30(8):965-70. doi: 10.1016/j.leukres.2005.11.011. Epub 2006 Jan 6. Leuk Res. 2006. PMID: 16406016

3

Eosinophilia: secondary, clonal and idiopathic.

Tefferi A, Patnaik MM, Pardanani A. Tefferi A, et al. Among authors: patnaik mm. Br J Haematol. 2006 Jun;133(5):468-92. doi: 10.1111/j.1365-2141.2006.06038.x. Br J Haematol. 2006. PMID: 16681635 Free article. Review.

4

Systemic mastocytosis: a concise clinical and laboratory review.

Patnaik MM, Rindos M, Kouides PA, Tefferi A, Pardanani A. Patnaik MM, et al. Arch Pathol Lab Med. 2007 May;131(5):784-91. doi: 10.5858/2007-131-784-SMACCA. Arch Pathol Lab Med. 2007. PMID: 17488167 Free article. Review.

5

Kit: molecule of interest for the diagnosis and treatment of mastocytosis and other neoplastic disorders.

Patnaik MM, Tefferi A, Pardanani A. Patnaik MM, et al. Curr Cancer Drug Targets. 2007 Aug;7(5):492-503. doi: 10.2174/156800907781386614. Curr Cancer Drug Targets. 2007. PMID: 17691909 Review.

6

The complete evaluation of erythrocytosis: congenital and acquired.

Patnaik MM, Tefferi A. Patnaik MM, et al. Leukemia. 2009 May;23(5):834-44. doi: 10.1038/leu.2009.54. Epub 2009 Mar 19. Leukemia. 2009. PMID: 19295544 Review.

7

Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML.

Tefferi A, Lim KH, Abdel-Wahab O, Lasho TL, Patel J, Patnaik MM, Hanson CA, Pardanani A, Gilliland DG, Levine RL. Tefferi A, et al. Among authors: patnaik mm. Leukemia. 2009 Jul;23(7):1343-5. doi: 10.1038/leu.2009.59. Epub 2009 Mar 19. Leukemia. 2009. PMID: 19295549 Free PMC article. No abstract available.

8

Molecular diagnosis of myeloproliferative neoplasms.

Patnaik MM, Tefferi A. Patnaik MM, et al. Expert Rev Mol Diagn. 2009 Jul;9(5):481-92. doi: 10.1586/erm.09.29. Expert Rev Mol Diagn. 2009. PMID: 19580432 Review.

9

JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival.

Tefferi A, Lasho TL, Patnaik MM, Finke CM, Hussein K, Hogan WJ, Elliott MA, Litzow MR, Hanson CA, Pardanani A. Tefferi A, et al. Among authors: patnaik mm. Leukemia. 2010 Jan;24(1):105-9. doi: 10.1038/leu.2009.225. Epub 2009 Oct 22. Leukemia. 2010. PMID: 19847199

10

Age and platelet count are IPSS-independent prognostic factors in young patients with primary myelofibrosis and complement IPSS in predicting very long or very short survival.

Patnaik MM, Caramazza D, Gangat N, Hanson CA, Pardanani A, Tefferi A. Patnaik MM, et al. Eur J Haematol. 2010 Feb 1;84(2):105-8. doi: 10.1111/j.1600-0609.2009.01373.x. Epub 2009 Nov 6. Eur J Haematol. 2010. PMID: 19895568

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

443 results

Search Page

Filters